is tirzepatide a prescription drug FDA confirms shortage still over, gives compounders grace period Trava tirzepatide: complete guide to

[82] The trial reported cumulative occurrence of major adverse cardiovascular events, a primary end-point event of the trial, for 569 of the 8803 patients in the semaglutide group, which were 6.5% of the participants, and for 701 of the 8801 patients in the placebo group, which were 8% of the participants, showing relative 18.8% less major adverse cardiovascular events, such as death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, occurring for participants who had received semaglutide in the trial relative to those who had received placebo over the course of around 48 months, or 34.213.7 months, which was the mean (SD) total duration of the participants in either group's exposure to the placebo or semaglutide during the trial

References Murakami T, Inagaki N, Kondoh H

Anti-LOX sharply increased penile length and exposed length by 15% and 9% respectively, this lengthening effect was more obvious in Anti-LOX + VED group (26% and 19%, respectively)

PLoS ONE 2018 found that GLP-1R agonists did not excite human dorsal-root-ganglion nociceptors directly or alter capsaicin/TRPV1 responses, but did enhance ATP responses